1. Pink Sheet
  2. >>Geography
  3. >>International

Global Medical Sciences Group Looks At Benefits, Challenges And Risks Of Using RWD

 
• By Vibha Sharma

The non-profit Council for International Organizations of Medical Sciences (CIOMS) has issued draft recommendations on using real-world evidence for the approval, use and reimbursement of medicinal products.

Background image of computer screen showing electronic medical records application with computer lab
RWD can complement data generated from randomized control trials • Source: Alamy

The increasing importance of real-world data (RWD) in clinical development and regulatory decision-making has prompted the Council for International Organizations of Medical Sciences to issue a new consensus report on this topic.

Key Takeaways

  • Real-world evidence (RWE) is well accepted by drug regulators for satisfying post-approval safety monitoring requirements, but there is now increasing willingness for its use...

The draft CIOMS report – published on 6 June for stakeholder consultation – aims to inform discussions about the use of RWD and real-world evidence (RWE) for regulatory and health...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from International

How Pharma Companies Can Mitigate The Impact Of US Tariffs On The Supply Chain

 
• By Ewan Townsend

If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.

EMA Touts Faster Global Post-Approval Changes Via Regulatory Reliance

 
• By Eliza Slawther

The European Medicines Agency says that a regulatory reliance pilot that it is supporting to speed up assessments of post-approval changes appears to be accelerating evaluation timelines in non-EU countries.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.

Quotable: Top Experts On Policy Hot Topics

 
• By Anabel Costa-Ferreira

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.

More from Geography

How Pharma Companies Can Mitigate The Impact Of US Tariffs On The Supply Chain

 
• By Ewan Townsend

If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.

Japan Price Cuts For Epkinly and Lunsumio Following CEA

 
• By Lisa Takagi

Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.